Pharmed Limited Unlisted Shares
About The Company
Strong
Market Position
Consistent
YoY Growth
Experienced
Management
Key Indicators
A snapshot of Pharmed Limited Unlisted Shares's financial health, valuation multiples and capital efficiency at a glance.
Pricing Trends
Financial Performance
| Indicators | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 528.6 | 487.3 | 436.0 | 359.6 | 286.3 | 319.9 | 273.4 | 233.0 |
| Expense | 417.2 | 403.7 | 389.1 | 302.0 | 234.4 | 286.3 | 249.2 | 214.1 |
| EBITDA | 111.4 | 83.6 | 46.9 | 57.6 | 51.9 | 33.6 | 24.1 | 18.9 |
| Other Cost | 5.3 | 5.4 | 3.6 | 2.6 | 2.3 | 2.2 | 2.4 | 2.3 |
| PBT | 106.2 | 78.2 | 43.2 | 55.0 | 49.6 | 31.4 | 21.7 | 16.6 |
| Tax Expense | 25.3 | 19.8 | 10.2 | 12.7 | 12.2 | 7.4 | 6.6 | 5.4 |
| PAT | 80.8 | 58.4 | 33.0 | 42.3 | 37.4 | 24.0 | 15.1 | 11.2 |
| Other Inc./Exp. | -1.6 | 0.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Income | 79.3 | 58.1 | 33.0 | 42.3 | 37.4 | 24.0 | 15.1 | 11.2 |
| Shares O/S | 0.43 | 0.43 | 0.40 | 0.40 | 0.40 | 0.40 | 0.40 | 0.40 |
| EPS (₹) | 187.51 | 135.28 | 76.90 | 98.40 | 86.90 | 55.80 | 35.20 | 26.10 |
| Rev. Growth % | 8.5% | 11.8% | 21.2% | 25.6% | -10.5% | 17.0% | 17.3% | — |
| EBITDA Mgn % | 21.1% | 17.2% | 10.8% | 16.0% | 18.1% | 10.5% | 8.8% | 8.1% |
| Net Mgn % | 15.0% | 11.9% | 7.6% | 11.8% | 13.1% | 7.5% | 5.5% | 4.8% |
| EPS Growth | 38.6% | 75.9% | -21.8% | 13.2% | 55.7% | 58.5% | 34.9% | — |
Registered Address
Management Team
Download Financial Results
Frequently Asked Questions
Still have questions?
Our expert team typically responds within 30 minutes during market hours.
About Pharmed Limited Unlisted Shares
Pharmed Limited is one of the fastest-growing pharmaceutical companies, established in 1946. Over seven decades, the company has helped millions of people improve their quality of life and carry forward its legacy of "Caring for India". Headquartered in India's Silicon Valley, Bangalore, Pharmed Limited has become a renowned company among the Indian medical fraternity and provides a wide range of innovative products.
Pharmed Ltd is a pharmaceutical company that manufactures and markets medicine in many medical fields, like orthopaedics, gynaecology, cardiology, and many more. It is one of the leading Pharmaceutical companies in India. Additionally, it has many brands under its belt; some examples are MGD3, Supracal, Cartigen, Absoult and many more. Moreover, Pharmed Ltd is backed by many investors and stakeholders.
It promotes these products among dermatologists, Physicians, orthopedic surgeons, Gynaecologists, etc. On this page, we will discuss Pharmed share price, financial performance, and other information in detail.
Different Brands of Pharmed Limited
Pharmed Pharmaceuticals Limited made its name in the pharma industry for its high-quality and evidence-based products. Let's have a look at the different brands that come under Pharmed Limited:
MGD3
It is the first Indian brand that comes under Pharmed Limited offering bioavailable magnesium to treat subclinical magnesium deficiency. MGD3 is beneficial in providing the body with Vitamin D and offering therapeutic effects.
Supracal
Supracal is one of the popular brands under Pharmed Pharmaceuticals Limited that offers calcium citrate, which is considered safe organic calcium. It is available in acid-independent and best-absorbed form.
Cartigen
Cartigen is the first Indian brand of Glucosamine, which is used to keep joints healthy and proven in treating the conditions of osteoarthritis.
Absoult
It is the popular brand of Pharmed Limited that offers the essential vitamins and minerals to treat various chronic diseases. Absolut is generally known for its health benefits of green tea extract.
Tendocare
As the name suggests, Tendocare is a brand which provides medicines for treating tendon degeneration. Pharmed uses this brand to manufacture products that treat the main cause of tendinopathies.
FOL 123 MF
FOL 123 MF is a popular brand in India that comes under Pharmed Pharmaceuticals Ltd, which targets women's problems during pregnancy and lactation. It offers the benefits of iodine with DHA in the form of tablets.
Apart from the above, Pharmed also has other brands, including ProLife, OsteoCytic, and Synertab, which target the specific issue people face in real life.
An Overview of Pharmed Limited Financial Performance
Pharmed Limited remains in the limelight and is considered one of the preferable investment options among retail investors. Since the company is active in the unlisted share market, its financial performance might impact the Pharmed share price. That's why it is essential to have an overview of its financial performance.
Particulars (in Rs. cr) | FY2022 | FY2023 | FY2025 |
Revenue | 359.6 | 436 | 528.6 |
Expenses | 302 | 389.1 | 417.2 |
EBITDA | 57.6 | 46.9 | 111.4 |
EBITDA Margin | 16% | 10.80% | 21.10% |
PAT | 42.3 | 33 | 80.8 |
Net Margin | 11.80% | 7.60% | 15% |
EPS | 98.4 | 76.9 | 187.5 |
Total Assets | 262.3 | 289.8 | 450.3 |
Reserves | 198.7 | 230.2 | 358 |
As per the analysis of Pharmed Pharmaceuticals Limited, the company recorded a growth in its operating revenue and net profit. It is also vital for investors to understand that Pharmed Limited recorded stellar growth in the financial year 2021-2022, in which its financial metrics increased.
In FY22, the company made Rs 359.6 Cr, then grew to Rs 436 Cr and finally hit Rs 528.6 Cr in FY2025. So, demand for their products like MGD3, calcium & bone health (Supracal), orthopaedics (Cartigen), lifestyle supplements (Absolut) and Tendocare clearly isn’t slowing down. They are selling more across specialisations like orthopaedics, gynaecology, dermatology, etc., and that can be seen as revenue is increasing.
But growth isn’t useful if it doesn’t make money, right?
FY23 was a bit weak, as expenses shot up to Rs389 Cr and profits (PAT) fell to just Rs33 Cr. Margins also dropped, and net margin fell to 7.6%. Something clearly squeezed profits that year (maybe higher costs or expansion spending).
But in FY25, expenses stayed controlled at Rs 417 Cr, but revenue jumped, so EBITDA margin improved to 21.1% and net profit climbed to Rs 80.8 Cr.
EPS jumped to Rs 187.5, which is more than double compared to FY23. That’s a strong signal for valuation if someone is tracking its unlisted share price.
Operational strength is visible in the margin recovery. EBITDA margin improved from 10.8% in FY23 to 21.1% in FY25, reflecting cost efficiency and better pricing realisation.
Net profit surged to Rs 80.8 Cr in FY25, nearly 2.5x FY23 levels. This led to an exceptional jump in EPS to Rs 187.5, a key positive for valuation if someone is tracking its unlisted share price.
Assets almost doubled in 3 years (Rs 262 Cr to Rs 450 Cr), and reserves increased to Rs 358 Cr, which means the company is building strength for the long term with low debt pressure.
Overall, FY25 shows the business is back to healthier profitability, with better cost management and improved revenue conversion.
For unlisted investors, this matters because a consistent FY26 will determine whether Pharmed’s shares can justify a higher valuation. Right now, the direction looks positive, but stability will be the real test.
Pharmed Share Price History
If we look at the price trend of Pharmed Ltd in the last year, it showed a regular spike in value from August to December 2022 and stood at Rs 420 per equity share. However, Pharmed share price showed growth and touched a mark of Rs 450 per equity share in the early months of 2023. The biggest growth Pharmed Limited recorded in its share price was during May and June 2023, when its share price increased from Rs 580 per equity share to Rs 1000 per equity share. It means the company grew almost 40% in the past few months, which is a positive sign for the investors.
If we take a look at the history of Pharmed Ltd share prices, we can see that the company has been performing quite well in the unlisted share market. The company started offering its unlisted shares in 2019. At that time, the shares were listed at a price of ₹200. As of December 2023, the unlisted share price of Pharmed Ltd is ₹920.
Pharmed unlisted share price has steadily climbed from Rs 500 to Rs 600 in mid-FY23 to nearly Rs 1,250–Rs 1,300 in FY25, reflecting improving business fundamentals instead of any hype.
This marks a 2.5X ROI for the people who invested in 2023.
Why Buy Pharmed Limited Unlisted Shares
One of the main reasons to buy Pharmed Ltd unlisted shares is the company’s financials.
Pharmed Pharmaceuticals Limited has shown a clear turnaround in its financial performance, making its unlisted shares worth tracking for long-term investors. After a weak FY23, when rising expenses compressed margins and profits, the company has delivered a strong recovery by FY25. Revenue growth has remained consistent, rising from Rs 359.6 crore in FY22 to Rs 528.6 crore in FY25, reflecting steady demand across key therapy segments such as orthopaedics, gynaecology, dermatology, calcium and bone health, and lifestyle supplements.
What strengthens the investment case is the sharp improvement in profitability. Net profit increased to Rs 80.8 crore in FY25, nearly 2.5 times FY23 levels, while net margins recovered to 15%. EBITDA margin also expanded meaningfully to 21.1%, indicating better cost control and improved pricing power. This operating recovery translated directly into shareholder metrics, with EPS rising sharply to Rs 187.5, more than double FY23 levels.
The balance sheet has also strengthened. Total assets have grown from Rs 262 crore to Rs 450 crore over 3 years, while reserves increased to Rs 358 crore, showing internal capital generation and low dependence on debt. This financial stability gives Pharmed room to scale operations without excessive balance-sheet risk.
Check Out Pharmed Share Price On Stockify
As you have an overview of Pharmed Pharmaceuticals Ltd in the last year, you must keep updated with its current share price. You can easily check Pharmed share price in India on Stockify. Our team of expert brokers keeps updating the share price based on fresh market data. Right now, the unlisted share price of Pharmed Limited is Rs 832 per equity share.
Check Share Price of Other Unlisted Companies Hassle-Free
Are you looking to buy trending unlisted shares to diversify your investment portfolio? Look no further than Stockify, India's trusted online trading platform, to buy or sell pre-IPO shares hassle-free. We have top-performing unlisted companies like Tata Technologies, OYO, HDFC Securities, Capgemini, etc. Let's have a look at the top investing options for you:
